EntryPoint Capital LLC Acquires Shares of 253,668 Standard BioTools Inc. $LAB

EntryPoint Capital LLC acquired a new stake in shares of Standard BioTools Inc. (NASDAQ:LAB) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 253,668 shares of the company’s stock, valued at approximately $274,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. HighTower Advisors LLC increased its holdings in shares of Standard BioTools by 10.8% during the first quarter. HighTower Advisors LLC now owns 102,791 shares of the company’s stock valued at $111,000 after acquiring an additional 10,000 shares in the last quarter. Nuveen LLC bought a new position in shares of Standard BioTools during the first quarter valued at $862,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Standard BioTools by 4.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,443,060 shares of the company’s stock valued at $2,639,000 after acquiring an additional 110,411 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Standard BioTools by 0.4% during the first quarter. Vanguard Group Inc. now owns 17,225,250 shares of the company’s stock valued at $18,603,000 after acquiring an additional 69,104 shares in the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in shares of Standard BioTools by 115.6% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock valued at $29,000 after acquiring an additional 14,541 shares in the last quarter. 53.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on LAB shares. Cowen downgraded Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Wall Street Zen upgraded Standard BioTools from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, TD Cowen downgraded Standard BioTools from a “buy” rating to a “hold” rating and set a $1.55 price target for the company. in a report on Wednesday, August 13th. Three investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, Standard BioTools currently has an average rating of “Hold” and a consensus target price of $1.55.

Standard BioTools Stock Performance

NASDAQ LAB opened at $1.27 on Friday. Standard BioTools Inc. has a one year low of $0.92 and a one year high of $2.32. The stock has a 50-day moving average of $1.27 and a 200 day moving average of $1.19. The company has a market capitalization of $485.13 million, a price-to-earnings ratio of -3.97 and a beta of 1.32.

Insider Buying and Selling

In other Standard BioTools news, Director Casdin Partners Master Fund, L acquired 150,000 shares of Standard BioTools stock in a transaction that occurred on Friday, August 15th. The stock was bought at an average cost of $1.22 per share, for a total transaction of $183,000.00. Following the acquisition, the director owned 59,750,000 shares of the company’s stock, valued at $72,895,000. This represents a 0.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders bought 358,220 shares of company stock valued at $442,446. 23.16% of the stock is currently owned by company insiders.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.